Weichert JP, Clark PA, Kandela IK, Vaccaro AM, Clarke W, Longino MA, Pinchuk AN, Farhoud M, Swanson KI, Floberg JM, Grudzinski J, Titz B, Traynor AM, Chen HE, Hall LT, Pazoles CJ, Pickhardt PJ, Kuo JS. Alkylphosphocholine Analogs for Broad Spectrum Cancer Imaging and Therapy. Science Transl Medicine 6, 240ra75, 1-10, June 11, 2014. (Cover Article)
Pivotal manuscript describing in great detail the scope of preclinical and clinical imaging of 124I-NM404 and optical versions of NM404 as well as biological mechanisms of uptake and retention in cancer cells and cancer stem cells. Cited 137 times.
Zhang R, Schroeder A, Grudzinski J, Rosenthal E, Warram J, Pinchuk A, Eliceiri K, Kuo J, Weichert J. Beyond the Margins: Real-Time Detection of Cancer with Targeted Fluorophores. Nature Reviews Clinical Oncology. 14(6): 347-364. 2017. doi:1038/nrclinic 2016.212. Published online 17 Jan 2017).
Extensive review of near-infrared fluorophores for optically guided surgical resection of tumors. This paper has been cited over 500 times.
Patel R, Hernandez R, Carlson P, Grudzinski J, Bates A, Jagodinski J, Erbe A, Marsh I, Aluicio-Sarduy E, Rakhmilevich A, Vail D, Engle J, Kim K, Bednarz B, Sondel P, Weichert J, and Morris Z. Low-dose targeted radionuclide therapy renders immunologically “cold” tumors responsive to immune checkpoint blockade. Science Transl Med. 14 Jul 2021:Vol. 13, Issue 602, eabb3631, DOI: 10.1126/scitranslmed.abb3631 (Cover Article)
This manuscript describes in detail our curative results when combining low dose Y-90, Lu-177, or Ac-225 radiolabeled NM600 with immune checkpoint inhibitors in several tumor types. T cell memory was induced which rejected subsequent cancer cell challenges. Cited 158 times.
Zhang RR, Choi, C, Brunnquell CL, Hernandez R, Pinchuk AN, Grudzinski JG, McMillan AB, Clark PA, Jeffrey J, Audhya AW, Kuo JS, Weichert Next Generation Cancer Magnetic Resonance Imaging with Tumor-Targeted Alkylphosphocholine Metal Analogs. Invest Radiol: Investigative Radiology, 57(10):655-663, October 2022.
First article describing our first-in-class tumor-selective MR contrast agent, Gd-NM600.